Adverse Event Profile in Tigilanol Tiglate Phase 2 Trials: Local Versus Systemic Effects

The most informative human safety data on tigilanol tiglate to date comes from QBiotics Group's Phase 1 and Phase 2 trials of the pharmaceutical-grade injectable formulation, administered intratumourally for solid tumour indications. The adverse event profile reported in those studies is distinctive: a high proportion of events are local to the injection site, transient, and grade 1–2 in severity. Severe systemic toxicity has been uncommon. Understanding this pattern matters for anyone interpreting the literature, and helps clarify what the published research does — and does not — say.

What the trials measured

The principal Phase 1 dose-escalation trial in adult patients with cutaneous and subcutaneous tumours is summarised on ClinicalTrials.gov as NCT02380794, and subsequent Phase 2 studies have extended the dataset across multiple histologies. Across these trials, investigators collected adverse events graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE). The full CTCAE framework is the standard for cancer-trial adverse-event reporting and provides the vocabulary used in subsequent peer-reviewed reports.

The local-versus-systemic distinction

A defining feature of the tigilanol tiglate safety profile is the separation between local and systemic events. Local events at the injection site — pain, oedema, erythema, exudation — were reported in the majority of treated patients in the published series but were generally short-lived, with most resolving within days to weeks. Systemic events, by contrast, were comparatively rare and most often grade 1–2 (mild to moderate). Serious systemic adverse events specifically attributed to the compound were uncommon in the published cohorts.

This profile is consistent with the compound's pharmacology. As an intratumoural agent with rapid local conversion and limited systemic exposure, tigilanol tiglate produces a strong local biological response while sparing distant tissue. The QBiotics tigilanol tiglate development summary describes this localisation in more detail.

Why this matters for interpretation

For readers comparing this clinical-trial literature to the dietary supplement category, the local-systemic distinction is important. The published safety profile applies to a specific dosage form (intratumoural injection of a purified, pharmaceutical-grade compound) and a specific patient population (adults with characterised solid tumours, monitored under trial conditions). Oral whole-berry extracts sold as dietary supplements are a different product, administered by a different route, with a different absorption and distribution profile. The injectable trial data does not directly speak to oral supplement safety, and supplement labels make no therapeutic claims on this basis.

What the injectable data does tell us is that the active compound, in a controlled clinical setting, has a measurable and reasonably predictable adverse event signature dominated by local effects. That is a useful baseline for any further research and is informative for understanding the compound's biology.

Selected reported event categories

Across the published Phase 1 and Phase 2 series, the most commonly reported event categories included injection-site pain, injection-site oedema, wound exudation as the tumour responded, and transient flu-like symptoms in a minority of patients. Where higher-grade events were observed, they were typically related to wound management rather than to systemic toxicity. A detailed account of the comparator veterinary safety dataset is available in the peer-reviewed paper De Ridder et al. in Veterinary and Comparative Oncology, which provides useful methodological context.

What ongoing trials are tracking

Active trials continue to refine the safety dataset, including in indications such as soft tissue sarcoma and head and neck squamous cell carcinoma. Updated registries on ClinicalTrials.gov are the most reliable source of currently recruiting and completed trials, including primary safety endpoints and dose-finding designs.

Quality and oversight in the supplement category

Outside of clinical trials, blushwood berry extract is sold as a dietary supplement and is not part of the published clinical safety dataset. Responsible suppliers in that category address quality and safety through independent batch testing, GMP-certified manufacturing, and transparent labelling. Blushwood Health's publicly available Eurofins reports show how a credible supplement supplier documents heavy metal and microbiology testing on every batch — separate from the pharmaceutical trial data, but the appropriate quality standard for the supplement category.

Related Articles

For more on how clinical responses are evaluated, see RECIST response criteria in tigilanol tiglate trials and MRI as a response biomarker in EBC-46 imaging.

This article is for informational purposes only. Blushwood berry extract dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.